Targacept 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 20, 2012
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On March 20, 2012, Targacept, Inc. issued a press release in which Targacept and its collaborator AstraZeneca reported top-line results from RENAISSANCE studies 4, 5 and 7, Phase 3 clinical trials of TC-5214 as an adjunct therapy to an antidepressant for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment, and announced that the two companies will not pursue a regulatory filing for TC-5214 as an adjunct treatment for patients with MDD. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.